Search company, investor...

Heron Therapeutics

Founded Year




Total Raised


Market Cap


Stock Price


About Heron Therapeutics

Heron Therapeutics (NASDAQ: HRTX) is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic technologies that improve medical care. Its advanced science, patented technologies, and approach to drug discovery and development allows it to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. The company was formerly known as A.P. Pharma and rebranded in August 2013. Heron Therapeutics was founded in 1983 and is based in San Diego, California.

Headquarters Location

4242 Campus Point Court Suite 200

San Diego, California, 92121,

United States


Missing: Heron Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Heron Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Heron Therapeutics Patents

Heron Therapeutics has filed 26 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Antiemetics
  • Trifluoromethyl compounds
patents chart

Application Date

Grant Date


Related Topics




Analgesics, Anesthesia, Local anesthetics, Acute pain, Dosage forms


Application Date


Grant Date



Related Topics

Analgesics, Anesthesia, Local anesthetics, Acute pain, Dosage forms



Latest Heron Therapeutics News

APONVIE Launched to Manage Postoperative Nausea and Vomiting

Mar 10, 2023

Heron Therapeutics Inc , a commercial-stage biotechnology company, announced APONVIE (aprepitant) injectable emulsion is now commercially available for intravenous (IV) use in adults for the prevention of postoperative nausea and vomiting (PONV). According to the company, when delivered via a single IV injection, APONVIE reaches drug levels associated with ≥97% receptor occupancy in the brain within 5 minutes and maintains therapeutic plasma concentrations for at least 48 hours. The company describes APONVIE as a ready-to-use, easy to administer, innovative IV formulation that ensures rapid and consistent exposure in patients undergoing surgery. Treatment with aprepitant resulted in approximately 50% fewer patients vomiting in the first 24 and 48 hours compared to the current standard-of-care, IV ondansetron. “There are approximately 36 million procedures in the U.S. each year involving patients with high to moderate risk for PONV, the patients who would benefit most from APONVIE. With superior efficacy and convenient dosing, APONVIE has the potential to reach several hundred million dollars in sales,” said Barry Quart, PharmD, chairman and chief executive officer of Heron. “This launch supports our ongoing commitment to delivering innovative solutions that improve the postoperative experience by addressing the two most common concerns after surgery, postoperative pain with ZYNRELEF and postoperative nausea and vomiting with APONVIE.” “PONV is one of the most common and concerning side effects patients experience after surgery. Inadequately managed PONV can result in poor patient outcomes, decreased patient satisfaction as well as increased healthcare costs,” said Randy Robbins, MD, managing partner at Valiant Anesthesia Associates PLLC. “Aprepitant is proven to be the most effective single agent to prevent PONV based on a comprehensive Cochrane meta-analysis. The launch of APONVIE will now allow providers to prevent PONV without the limitations of the current oral route of administration. We are very excited to see that physicians can now offer patients a more convenient IV push that delivers aprepitant in a rapid, consistent, and reliable way with the same 48-hour duration of effect, providing a better experience for patients postoperatively.” Share:

Heron Therapeutics Frequently Asked Questions (FAQ)

  • When was Heron Therapeutics founded?

    Heron Therapeutics was founded in 1983.

  • Where is Heron Therapeutics's headquarters?

    Heron Therapeutics's headquarters is located at 4242 Campus Point Court, San Diego.

  • What is Heron Therapeutics's latest funding round?

    Heron Therapeutics's latest funding round is PIPE.

  • How much did Heron Therapeutics raise?

    Heron Therapeutics raised a total of $12.46M.

  • Who are the investors of Heron Therapeutics?

    Investors of Heron Therapeutics include Great Point Partners, Broadfin Capital, Deep Track Capital and Iroquois Capital Group.

  • Who are Heron Therapeutics's competitors?

    Competitors of Heron Therapeutics include Cerecin, GangaGen, Portola Pharmaceuticals, Raptor Pharmaceutical Corp., Potentia Pharmaceuticals and 12 more.

Compare Heron Therapeutics to Competitors


Adriacell s.r.l is a biotech company focused in oncology pharmaceuticals founded in Basovizza (Trieste) in March 2004 by Prof. Christian Kuehne, an Austrian citizen.nThe company is leveraging its efforts and scientific expertise to successfully solve important worldwide health problems; in particular, it has been striving to develop a new class of anti-tumour therapeutics and to create a series of powerful diagnostics for the early detection of cancer progression. The company is also developing new and highly powerful delivery solutions through small molecules as the basis for a new class of anti-infective drugs.nAdriaCell owns a patented system that can be used for the study of events subsequent to DNA double strand breaks, a very important issue for cancer research and diagnostics. Adriacell is currently evaluating a new class of therapeutics for cancer; its main lead compound is about to enter the pharmacokinetic and toxicology phases.nAdriacell Vision is to become a leader biotech drug development company concentrated in the development of solutions (treatment and diagnostics) for tumours characterized by low probability of survival for patients and of anti infective agents. Thanks to future developments in research and test activities Adriacell solutions will hopefully become useful in a wider range of pathologies.

SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).


Respirics Inc. is a pulmonary drug delivery and development company located in Raleigh, North Carolina. The company is developing a line of branded inhalation drug products in its patented Acu-Breathe™ dry powder inhalers, and is working with pharmaceutical clients to enhance the delivery of their own compounds or formulations. Respirics combines proprietary inhalation technology with powder drug formulation expertise to develop unique drug delivery solutions. The company is committed to bringing effective, easy-to-use and affordable inhalation drug products to the patients who need them.

Bikam Pharmaceuticals

BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.

Janus Pharmaceuticals

Janus Pharmaceuticals Inc. (Janus) is a specialty pharmaceutical company identifying, acquiring and aggressively developing topical prescription products for treatment of skin infections. Determined to be the "Dermal Alternative", Janus has already established a strong intellectual property portfolio for topical anti-infective compounds that would be rapidly commercialized through fast regulatory pathways. Led by an accomplished management team and board located in the US and Japan, Janus has trans-Pacific network and resources in the biopharmaceutical industry.

Selectx Pharmaceuticals

SelectX Pharmaceuticals is a biopharmaceutical company that focuses on the discovery and development of small molecule antimicrobials and other therapeutics for unmet medical needs through the application of its Genetic Chemistry platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.